Giant Cell Arteritis Refractory to Interleukin‐6 and Interleukin‐17 Inhibition Treated With Upadacitinib Article Swipe
Related Concepts
Medicine
Interleukin
Refractory (planetary science)
Giant cell arteritis
Internal medicine
Pharmacology
Cytokine
Physics
Vasculitis
Disease
Astrobiology
Luke S. Vest
,
Ali Ahmad
,
Sanhitha Valasareddy
,
Nancy J. Phillips
,
Adam Kilian
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1002/acr2.70094
· OA: W4412724847
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1002/acr2.70094
· OA: W4412724847
Giant cell arteritis (GCA) is a granulomatous vasculitis that can involve both cranial and extracranial vessels. Although interleukin‐6 (IL‐6) receptor blockade is an established therapy, treatment options for medically refractory disease remain limited. We report a unique case of extracranial GCA refractory to glucocorticoids, azathioprine, tocilizumab (IL‐6 inhibitor), and secukinumab (IL‐17A inhibitor) that responded robustly to upadacitinib, a selective JAK1 inhibitor. To our knowledge, this is the first reported case of GCA demonstrating resistance to both IL‐6 and IL‐17 inhibition but clinical and imaging remission with JAK inhibition, highlighting the role of upadacitinib as a therapy for patients with GCA.
Related Topics
Finding more related topics…